Commercialising academic research
What we do
MRC Technology is the exclusive technology transfer agent for the UK’s Medical Research Council and is responsible for translating cutting edge scientific discoveries into commercial products.
In addition we have small molecule drug discovery and therapeutic antibody facilities, providing lead stage therapeutic assets to pharmaceutical and biotechnology companies.
Partnering, licensing and technology transfer
MRC Technology adds value to cutting edge scientific discoveries through strategic patent protection and creative licensing of intellectual property (IP) or through partnered research with MRC units and institutes (with an annual research budget of around US$ 530m/GBP£355). We also work with some of the world's other best academic organisations to develop their IP.
Small molecule drugs and therapeutic antibodies
Our Centre for Therapeutics Discovery (CTD) has been set-up to translate novel exciting biology into lead stage therapeutic assets with a clear pre-clinical and clinical developmental pathway. Bridging the gap between basic research and pre-clinical development, we develop innovative assays and pharma quality medicinal chemistry programmes from high quality hits.
Our Therapeutic Antibody Group (part of the Centre for Therapeutics Discovery), offers the chance to take advantage of its substantial antibody engineering know-how to target major life threatening and debilitating diseases.
News feed
MRCT are collaborating with the University of Bristol to develop orally available small molecule TrkA antagonists for treatment of chronic intractable pain.
MRC Technology’s Therapeutic Antibody Group and The University of Aberdeen work together on project to develop therapeutic against a novel cancer target, soluble CTLA-4.
Aptuscan, a spin out company based on research carried out at the MRC Cancer Cell Unit, has been acquired by Avacta, an AIM-listed biotechnology company.
MRC Technology announced today that they have entered into an agreement with the Association for International Cancer Research (AICR) to assist in the oversight and management of intellectual property (IP) arising from AICR-funded projects.